Table: Jcr Pharmaceuticals -2021/22 group forecast
30/09/2021 09:00
Sept 30 (Reuters) -
Jcr Pharmaceuticals Co., Ltd.
CONSOLIDATED EARNINGS ESTIMATES
(in billions of yen unless specified)
Full Year to Full Year to
Mar 31, 2022 Mar 31, 2022
LATEST PREVIOUS
FORECAST FORECAST
Sales 52.00 49.00
Operating 21.70 18.70
Recurring 21.70 18.70
Net 15.40 13.30
EPS 124.70 yen 107.68 yen
NOTE - Jcr Pharmaceuticals Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results